Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCTX Briacell Therap	$2.96 -4.8%	$3.55	$2.78 ▼ $29.40	$21.07M	1.3	570,618 shs	92,225 shs
DRRX DURECT	$0.63 +0.8%	$0.61	$0.48 ▼ $1.74	$19.29M	0.59	46,236 shs	21,342 shs
LIPO Lipella Pharmaceuticals	$0.90	$2.46	$0.62 ▼ $12.00	$4.02M	0.44	726,759 shs	19,002 shs
RLMD Relmada Therapeutics	$0.61 -9.4%	$0.58	$0.24 ▼ $4.47	$22.34M	0.65	970,419 shs	277,155 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCTX Briacell Therap	-4.82%	-3.27%	-6.62%	-25.44%	-82.14%
DRRX DURECT	+0.77%	-9.51%	+20.66%	-21.73%	-52.38%
LIPO Lipella Pharmaceuticals	0.00%	-45.45%	-69.18%	-65.25%	-76.11%
RLMD Relmada Therapeutics	-9.37%	-10.10%	-15.85%	+105.59%	-79.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BCTX Briacell Therap	3.0829 of 5 stars	3.5	5.0	0.0	3.3	0.0	0.6
DRRX DURECT	1.0831 of 5 stars	0.0	2.0	4.4	3.8	0.0	0.0
LIPO Lipella Pharmaceuticals	1.9689 of 5 stars	0.0	5.0	0.0	1.8	3.3	0.6
RLMD Relmada Therapeutics	4.8033 of 5 stars	3.1	5.0	4.4	2.6	4.2	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCTX Briacell Therap	3.00	Buy	$32.00	981.08% Upside
DRRX DURECT	2.00	Hold	N/A	N/A
LIPO Lipella Pharmaceuticals	0.00	N/A	N/A	N/A
RLMD Relmada Therapeutics	2.25	Hold	$5.00	719.67% Upside

Current Analyst Ratings Breakdown

Latest LIPO, BCTX, DRRX, and RLMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/22/2025	BCTX Briacell Therap	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCTX Briacell Therap	N/A	N/A	N/A	N/A	$1.76 per share	N/A
DRRX DURECT	$2.03M	9.57	N/A	N/A	$0.29 per share	2.16
LIPO Lipella Pharmaceuticals	$536.36K	7.50	N/A	N/A	$1.59 per share	0.57
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	$1.18 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCTX Briacell Therap	-$4.79M	-$8.32	N/A	N/A	N/A	N/A	-479.97%	-182.26%	N/A
DRRX DURECT	-$8.32M	-$0.15	N/A	N/A	N/A	-91.54%	-267.36%	-64.00%	8/12/2025 (Estimated)
LIPO Lipella Pharmaceuticals	-$5.02M	-$4.08	N/A	∞	N/A	-988.83%	-224.08%	-172.88%	N/A
RLMD Relmada Therapeutics	-$79.98M	-$2.51	N/A	N/A	N/A	N/A	-181.26%	-151.23%	8/6/2025 (Estimated)

Latest LIPO, BCTX, DRRX, and RLMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
6/13/2025	Q3 2025	BCTX Briacell Therap	-$1.76	-$1.64	+$0.12	-$1.64	N/A	N/A
5/14/2025	Q1 2025	LIPO Lipella Pharmaceuticals	N/A	-$0.64	N/A	-$0.64	N/A	$0.13 million
5/12/2025	Q1 2025	RLMD Relmada Therapeutics	-$0.31	-$0.58	-$0.27	-$0.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCTX Briacell Therap	N/A	N/A	N/A	N/A	N/A
DRRX DURECT	N/A	N/A	N/A	N/A	N/A
LIPO Lipella Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RLMD Relmada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCTX Briacell Therap	N/A	3.41	3.41
DRRX DURECT	N/A	1.23	1.22
LIPO Lipella Pharmaceuticals	N/A	6.21	6.21
RLMD Relmada Therapeutics	N/A	5.29	5.29

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCTX Briacell Therap	15.42%
DRRX DURECT	28.03%
LIPO Lipella Pharmaceuticals	74.31%
RLMD Relmada Therapeutics	45.24%

Insider Ownership

Company	Insider Ownership
BCTX Briacell Therap	5.73%
DRRX DURECT	3.20%
LIPO Lipella Pharmaceuticals	32.11%
RLMD Relmada Therapeutics	20.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCTX Briacell Therap	8	6.78 million	6.39 million	Optionable
DRRX DURECT	80	31.04 million	30.05 million	Optionable
LIPO Lipella Pharmaceuticals	4	4.47 million	3.03 million	Not Optionable
RLMD Relmada Therapeutics	10	33.19 million	26.32 million	Optionable

LIPO, BCTX, DRRX, and RLMD Headlines

Recent News About These Companies

Relmada Therapeutics, Inc. (RLMD) - Yahoo Finance

June 26 at 3:32 PM | finance.yahoo.com

RLMD - Relmada Therapeutics Inc Executives - Morningstar

June 24, 2025 | morningstar.comM

Relmada Therapeutics Appoints Dr. Raj S. Pruthi as Chief Medical Officer for Urology to Advance NDV-01 Program for Bladder Cancer

June 17, 2025 | quiverquant.comQ

Relmada Therapeutics Appoints Urology Expert Raj S. Pruthi, MD as CMO-Urology

June 17, 2025 | globenewswire.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) CFO Purchases $22,000.00 in Stock

May 21, 2025 | insidertrades.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2025 Earnings Call Transcript

May 14, 2025 | msn.com

Relmada Therapeutics, Inc. (RLMD) Q1 2025 Earnings Call Transcript

May 12, 2025 | seekingalpha.com

Relmada Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025 | globenewswire.com

Relmada Therapeutics to Report First Quarter 2025 Financial Results on Monday, May 12, 2025

May 8, 2025 | globenewswire.com

Relmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder Cancer

April 28, 2025 | nasdaq.com

Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025

April 28, 2025 | globenewswire.com

Relmada Therapeutics to hold a virtual meeting

April 27, 2025 | markets.businessinsider.com

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

April 27, 2025 | globenewswire.com

Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data

April 24, 2025 | globenewswire.com

UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025

April 14, 2025 | globenewswire.com

Relmada Therapeutics To Present NDV-01 Data at AUA2025

April 14, 2025 | globenewswire.com

Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Call Transcript

March 29, 2025 | msn.com

Q4 2024 Relmada Therapeutics Inc Earnings Call

March 29, 2025 | uk.finance.yahoo.com

Relmada reconsiders phase 2 plans to test magic mushroom extract for obesity

March 28, 2025 | fiercebiotech.comF

Relmada Therapeutics reports Q4 EPS (62c) vs. (84c) last year

March 28, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LIPO, BCTX, DRRX, and RLMD Company Descriptions

Briacell Therap NASDAQ:BCTX

$2.96 -0.15 (-4.82%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.02 +0.06 (+2.03%)

As of 06/27/2025 07:20 PM Eastern

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

DURECT NASDAQ:DRRX

$0.63 +0.00 (+0.77%)

As of 06/27/2025 04:00 PM Eastern

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.

Lipella Pharmaceuticals NASDAQ:LIPO

$0.90 0.00 (0.00%)

As of 06/27/2025 03:29 PM Eastern

Lipella Pharmaceuticals Inc., a biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. The company develops LP-10, a formulation of tacrolimus that has completed Phase 2a clinical trial for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; and LP-410, an oral liposomal formulation of tacrolimus for the treatment of oral graft-versus-host disease (GVHD). Lipella Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Pittsburgh, Pennsylvania.

Relmada Therapeutics NASDAQ:RLMD

$0.61 -0.06 (-9.37%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.64 +0.03 (+4.26%)

As of 06/27/2025 07:16 PM Eastern

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time